In vivo demonstration of an active tumor pretargeting approach with peptide nucleic acid bioconjugates as complementary systemElectronic supplementary information (ESI) available: Characterization of the PNAs used this study (Fig. S1-14), radio HPLC of [99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA (Fig. S15), melting temperatures (TM) for three complementary 17-mer PNA systems (Table S1), melting curves of different PNAs (Fig. S16), radio HPLC of the [99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA (original), in rat ar

A novel, promising strategy for cancer diagnosis and therapy is the use of a pretargeting approach. For this purpose, the non-natural DNA/RNA analogues Peptide Nucleic Acids (PNAs) are ideal candidates as in vivo recognition units due to their high metabolic stability and lack of unspecific accumula...

Full description

Saved in:
Bibliographic Details
Main Authors Leonidova, Anna, Foerster, Christian, Zarschler, Kristof, Schubert, Maik, Pietzsch, Hans-Jürgen, Steinbach, Jörg, Bergmann, Ralf, Metzler-Nolte, Nils, Stephan, Holger, Gasser, Gilles
Format Journal Article
LanguageEnglish
Published 14.09.2015
Online AccessGet full text

Cover

More Information
Summary:A novel, promising strategy for cancer diagnosis and therapy is the use of a pretargeting approach. For this purpose, the non-natural DNA/RNA analogues Peptide Nucleic Acids (PNAs) are ideal candidates as in vivo recognition units due to their high metabolic stability and lack of unspecific accumulation. In the pretargeting approach, an unlabeled, highly specific antibody-PNA conjugate has sufficient time to target a tumor before administration of a small fast-clearing radiolabeled complementary PNA that hybridizes with the antibody-PNA conjugate at the tumor site. Herein, we report the first successful application of this multistep process using a PNA-modified epidermal growth factor receptor (EGFR) specific antibody (cetuximab) and a complementary 99m Tc-labeled PNA. In vivo studies on tumor bearing mice demonstrated a rapid and efficient in vivo hybridization of the radiolabeled PNA with the antibody-PNA conjugate. Decisively, a high specific tumor accumulation was observed with a tumor-to-muscle ratio of >8, resulting in a clear visualization of the tumor by single photon emission computed tomography (SPECT). The first successful application of a pretargeting approach using a PNA-modified epidermal growth factor receptor specific antibody and a complementary 99m Tc-labeled PNA is presented.
Bibliography:10kDa
in rat and mouse (Fig. S18). See DOI
PNA
(Fig. S15), melting temperatures
Tc](Tc-Dpa)-(Cys-PEG
for three complementary 17-mer PNA systems (Table S1), melting curves of different PNAs (Fig. S16), radio HPLC of the
10.1039/c5sc00951k
M
99m
(original), in rat arterial blood plasma (Fig. S17), biodistribution of radiolabeled PNAs in Wistar rats (%ID mean ± SD) (Table S2), biodistribution of radiolabeled PNAs in Wistar rats (SUV mean ± SD) (Table S3), SPECT/CT comparison of the biodistribution of
T
[
Electronic supplementary information (ESI) available: Characterization of the PNAs used this study (Fig. S1-14), radio HPLC of
ISSN:2041-6520
2041-6539
DOI:10.1039/c5sc00951k